Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) last reported results for the quarter ended Jun 2026, with sales of ₹24 crore and net profit of ₹13 crore. The stock last traded at ₹73.1, a market capitalisation of ₹3,222 crore, on a P/E of 94.8. Over the past 52 weeks the stock has ranged between ₹26.3 and ₹73.9. Figures are as of 6 Oct 2026 and are not real time.
Shukra Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹73.1
- Market cap
- ₹3,222 cr
- Stock P/E
- 94.8
- Book value
- ₹2.05
- ROE
- 28.9%
- ROCE
- 37.0%
- Dividend yield
- 0.01%
- 52w high / low
- 73.9/26.3
Metrics as of 6 Oct 2026. Not real time.
Track Shukra Pharmaceuticals Ltd
Cruxal reads every Shukra Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Shukra Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 74%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 130%
- 10 Years
- 73%
- 5 Years
- 189%
- 3 Years
- 170%
- 1 Year
- 109%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 29%
Shukra Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹24 cr, up 380.0% from ₹5 cr a year earlier. Net profit was ₹13 cr, up 1200.0% year on year.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 7 | 6 | 4 | 6 | 12 | 6 | 4 |
| Operating profit | 4 | 7 | 1 | -0 | 27 | 1 | 19 |
| OPM % | 37% | 55% | 24% | -7% | 69% | 11% | 81% |
| Other income | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 18 |
| Tax % | 23% | 29% | 26% | -1,090% | 24% | 553% | 29% |
| Net profit | 3 | 5 | 1 | 2 | 20 | -2 | 13 |
| EPS (₹) | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.29 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Shukra Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 33 | 57 | 75 |
| Operating profit | 13 | 29 | 47 |
| OPM % | 39% | 51% | 62% |
| Net profit | 10 | 22 | 34 |
| EPS (₹) | 0.22 | 0.50 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Shukra Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 44 | 44 |
| Reserves | 19 | 46 |
| Borrowings | 4 | 5 |
| Other liabilities | 20 | 23 |
| Total liabilities | 87 | 117 |
| Fixed assets | 19 | 22 |
| CWIP | 2 | 12 |
| Investments | 0 | 0 |
| Other assets | 65 | 84 |
| Total assets | 87 | 117 |
As reported by the company. Total assets equal total liabilities by construction.
Shukra Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | 8 | 3 |
| Cash from investing | -1 | -14 |
| Cash from financing | -5 | 5 |
| Net cash flow | 2 | -6 |
| Free cash flow | 5 | -13 |
| CFO / operating profit | 92% | 17% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Shukra Pharmaceuticals Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | 37% |
| Debtor days | 98 | 148 |
| Inventory days | 447 | 320 |
| Days payable | 414 | 232 |
| Cash conversion cycle | 131 | 236 |
| Working capital days | 403 | 352 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Shukra Pharmaceuticals Ltd shareholding pattern
Promoters held 51.16% at Aug 2026, broadly unchanged since Sep 2025. DIIs 0.11%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.74% |
| No. of shareholders | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 | 28,384 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Shukra Pharmaceuticals Ltd corporate filings
- Reg 74(5)Company Updatelow impact
- Shukra Pharmaceuticals completes warrant conversion, issuing 17.35 lakh equity shares worth Rs.4.63 crore, increasing paid-up capital to Rs.44.25 croreOthershigh impact
Cruxal's analysis: Shukra Pharmaceuticals has successfully converted 17.35 lakh warrants into equity shares…
Read the full analysis - Shukra Pharmaceuticals Clarifies Corporate Update on 6 October 2026Company Updatelow impact
Cruxal's analysis: The company issued a clarification on 6 October 2026, with no specific financial or…
Read the full analysis - Shukra Pharmaceuticals Limited Passes Resolutions for Name Change and MOA Amendment via Postal Ballot with Over 99% SupportAGM/EGMhigh impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has successfully obtained over 99% approval for two key…
Read the full analysis - Shukra Pharmaceuticals Passes Key Resolutions at 33rd AGM with Over 99.8% Voting Support, Including Final Dividend and Director AppointmentsAGM/EGMhigh impact
Cruxal's analysis: Shukra Pharmaceuticals Limited held its 33rd AGM on September 28, 2026, with resolutions…
Read the full analysis - Shukra Pharmaceuticals Limited concludes 33rd Annual General Meeting; approves financial statements and dividend for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has successfully concluded its 33rd Annual General Meeting…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Shukra Pharmaceuticals Ltd publishes routine newspaper notice regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has released a newspaper publication in compliance with Regulation…
Read the full analysis - Shukra Pharmaceuticals issues corrigendum to postal ballot for name change to Shukra Medtech LimitedAGM/EGMlow impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has issued a corrigendum to its August 22, 2026, postal…
Read the full analysis - Shukra Pharmaceuticals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Shukra Pharmaceuticals has filed its Annual Report for the financial year 2025-26 in…
Read the full analysis - Shukra Pharmaceuticals Announces 33rd AGM for September 28, 2026, with 1% Final Dividend DeclarationAGM/EGMlow impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has scheduled its 33rd Annual General Meeting (AGM) for…
Read the full analysis - Shukra Pharmaceuticals Limited Reschedules 33rd Annual General Meeting to September 28, 2026AGM/EGMlow impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has announced the rescheduling of its 33rd Annual General…
Read the full analysis - Shukra Pharmaceuticals Limited announces record date for final dividend of INR 0.01 per share for FY 2025-26 Corp Actionlow impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has fixed Monday, September 21, 2026, as the record date…
Read the full analysis - Shukra Pharmaceuticals Ltd. Allots 11.73 Lakh Equity Shares via Warrant Conversion, Raising INR 3.13 CroreOthersmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd. has completed the allotment of 11.73 lakh equity shares to…
Read the full analysis - Shukra Pharmaceuticals Ltd publishes routine newspaper notice for regulatory complianceCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has fulfilled a standard regulatory requirement under Regulation…
Read the full analysis - Shukra Pharmaceuticals to pivot into MedTech, proposes name change to Shukra Medtech LimitedAGM/EGMmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder…
Read the full analysis - Shukra Pharmaceuticals to pivot into MedTech with proposed name change and expanded business objectsBoard Meetingmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has announced a strategic pivot, seeking shareholder…
Read the full analysis - Shukra Pharmaceuticals Ltd releases media updateCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has issued a media release. The filing contains no specific…
Read the full analysis - Shukra Pharmaceuticals to consider name change and alteration of object clause at upcoming board meetingBoard Meetingmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd. has announced a board meeting scheduled for August 22, 2026…
Read the full analysis - Shukra Pharmaceuticals Ltd completes listing formalities on the National Stock Exchange (NSE)Company Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd has formally completed the listing process on the National…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.